Dosimetry model for radioactivity localized to intestinal mucosa

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 3, 2004, Pages 293-307

  Fisher, Darrell ^a   Rajon, Didier ^b   Breitz, Hazel ^c   Goris, Michael ^d   Bolch, Wesley ^b   Knox, Susan ^d  

^a PACIFIC NORTHWEST NATIONAL LABORATORY   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Poniard Pharmaceuticals Inc   (United States)

^d STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dosimetry; Intestinal mucosa; Intestinal tract; MIRD; Monoclonal antibodies; Radiation effects; Yttrium 90

Indexed keywords

RADIOPHARMACEUTICAL AGENT; STREPTAVIDIN; UNCLASSIFIED DRUG; YTTRIUM 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID Y 90; YTTRIUM 90;

ARTICLE; DOSE RESPONSE; DOSIMETRY; DRUG PROTEIN BINDING; DRUG UPTAKE; INTESTINE MUCOSA; INTESTINE WALL; NONHUMAN; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIOACTIVITY; SCINTILLATION CAMERA;

HUMANS; INTESTINAL MUCOSA; MODELS, BIOLOGICAL; MONTE CARLO METHOD; RADIATION DOSAGE;

EID: 3142686777     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/1084978041425043     Document Type: Article

References (30)

1. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219.
2. Breitz HB, Fisher DR, Wessels BW. Marrow toxicity and radiation dose estimates from rhenium-186-labeled monoclonal antibody. J Nucl Med 1998;39:1746.
3. Siegel JA, Wessels BW, Watson EE, et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunocon Radiopharm 1990;3:213.
4. Press OW, Eary JF, Appelbaum FR, et al. Phase II trial of I-131-B1 (anti-CD20) antibody therapy with autologous stem-cell transplantation for relapsed B-cell lymphomas. Lancet 1995;346:336.
5. Matthews DC, Appelbaum FR, Eary JF, et al. Development of a marrow transplant regimen for acute leukemia using targeted hematopoietic irradiation delivered by 1-131-labeled anti-CD45 antibody, combined with cyclophosphamide and total-body irradiation. Blood 1995;85:1122.
6. Knox SJ, Goris ML, Weiner LM, Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res 2000;6:406.
7. 90Y-DOTA-biotin. J Nucl Med 2000;41(1):131.
8. Breitz HB, Fisher DR, Goris ML, et al. Radiation-absorbed dose estimation for Y-90-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm 1999;14(5):381.
9. Loevinger R, Budinger TF, Watson EE, et al. MIRD Primer for Absorbed Dose Calculations (revised). New York: The Society of Nuclear Medicine, 1991.
10. Snyder WS, Ford MR, Warner GG, et al. Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. In: MIRD pamphlet no. 5, J Nucl Med 1969;10(suppl. 3):5.
11. Snyder WS, Ford MR, Warner GG. Estimates of specific absorbed fractions for photon sources uniformly distributed in various organs of a heterogeneous phantom. MIRD pamphlet No. 5 (revised). New York: The Society of Nuclear Medicine, 1978.
12. Eve IS. A review of the physiology of the gastrointestinal tract in relation to radiation doses from radioactive materials. Health Phys 1966;12:131.
13. Stubbs JB, Evans JF, Stabin MG. Radiation absorbed doses to the walls of hollow organs. J Nucl Med 1998;39:1989-1995.
14. Mardirossian G, Tagesson M, Blanco P, et al. A new rectal model for dosimetry applications. J Nucl Med 1999;40:1524.
15. Poston JW Jr, Kodimer KA, Bolch WE, et al. Calculation of absorbed energy in the gastrointestinal tract. Health Phys 1996;71(3):300.
16. Poston JW Jr, Kodimer KA, Bolch WE, et al. A revised model for the calculation of absorbed energy in the gastrointestinal tract. Health Phys 1996;71(3):307.
17. Jönsson L, Liu X, Jönsson B-A, et al. A dosimetry model for the small intestine incorporating intestinal wall activity and cross-doses. J Nucl Med 2002;43:1657.
18. 99mTc-sestamibi in a new small intestinal dosimetry model. Cancer Biother Radiopharm 2003;18(2):217.
19. Fanucci A, Cerro P, Fanucci E. Normal small-bowel measurements by enteroclysis. Scand J Gastroenterol 1988;23:574.
20. Silverstein FR, Kimmey M, Martin R, et al. Ultrasound and the intestinal wall: Experimental methods. Scand J Gastroenterol Suppl 1986;123:34.
21. Pallotta N, Baccini F, Corazziari E. Small intestine contrast ultrasonography. J Ultrasound Med 2000; 19:21.
22. Haber HP, Stern M. Intestinal ultrasonography in children and young adults: Bowel wall thickness is age dependent. J Ultrasound Med 2000;19(5):315-321.
23. Dialer I, Hundt C, Bertele-Harms RM, et al. Sonographic evaluation of bowel wall thickness in patients with cystic fibrosis. J Clin Gastroenterol 2003; 37(1):55.
24. Pohl M, Krackhardt B, Posselt HG, et al. Ultrasound studies of the intestinal wall in patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 1997;25:317.
25. Thiele J, Kloppel R, Schulz HG. CT-Sellink-a new method of evaluating the intestinal wall. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfar 1993;159: 213.
26. Wiesner W, Mortele KJ, Ji H, et al. Normal colonic wall thickness at CT and its relation to colonic distension. J Comput Assist Tomogr 2002;26(1):102.
27. Lee JK, Marcos HB, Semelka RC. MR imaging of the small bowel using the HASTE sequence. Am J Roentgenol 1998;170(6):1457.
28. Nelson WR, Hirayama H, Rogers DWO. The EGS4 code system. Report no. 265. Stanford Linear Accelerator Center, Menlo Park, California, 1985.
29. Watson EE, Stabin MG, Davis JL, et al. A model of the peritoneal cavity for use in internal dosimetry. J Nucl Med 1989;30:2002.
30. Cristy M, Eckerman KF. Specific absorbed fractions of energy at various ages from internal photon sources. ORNI/FM-8381. Oak Ridge, TN: Oak Ridge National Laboratory, 1987.